Moderator Raoul S. Concepcion, MD, introduces a panel discussion that highlights specific clinical information on therapeutic advances and remaining unmet challenges in the treatment of patients with castration-resistant prostate cancer (CRPC). The conversation includes expert perspectives from Philippa J. Cheetham, MD, Kenneth M. Kernen, MD, A. Oliver Sartor, MD, Neal D. Shore, MD, and Michael E. Williams, MD.

CRPC is defined by disease progression despite the administration of androgen deprivation therapy (ADT), notes Concepcion. Additionally, CRPC is characterized by a serum testosterone level less than 50 ng/dL and a rise in serum PSA. Patients without detectable metastases have M0 disease whereas those with metastases detected by radiographic imaging, either CT scan or NaF PET/CT, are said to have M1 CRPC, notes Concepcion.

In the last four years, five novel agents have demonstrated improved survival in metastatic CRPC and have been granted FDA approval, Concepcion points out. These newly approved agents include cabazitaxel, sipuleucel-T, abiraterone acetate, enzalutamide, and radium-223.